<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of disorders characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting dyspoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> range from those with a relatively indolent course (e.g., <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with or without ringed sideroblasts) to more aggressive disorders (e.g., <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>], and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>]), which may exhibit a clinical course indistinguishable from <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Supportive care is the standard treatment for most patients, particularly those who are elderly, with the judicious use of blood components and antibiotics </plain></SENT>
<SENT sid="3" pm="."><plain>For younger patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, antileukemic therapy might be considered, since the outcome is similar to that of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Promising new chemotherapy agents currently in clinical trials include the <z:chebi fb="0" ids="50276">topoisomerase I inhibitor</z:chebi>, topotecan </plain></SENT>
<SENT sid="5" pm="."><plain>The only curative treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is allogeneic bone marrow transplantation, with long-term survival in approximately 40%, but with treatment-related <z:hpo ids='HP_0011420'>deaths</z:hpo> in 25%-40% </plain></SENT>
<SENT sid="6" pm="."><plain>Factors predicting outcome include age, cytogenetics, number of blasts, and others </plain></SENT>
<SENT sid="7" pm="."><plain>Myeloid growth factors (e.g., G-CSG, GM-CSF), increase the granulocyte count in most patients and may be useful in the setting of an active <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, although the prophylactic use of these agents does not improve survival </plain></SENT>
<SENT sid="8" pm="."><plain>Erythropoietin increases the hematocrit in about 20% of patients </plain></SENT>
<SENT sid="9" pm="."><plain>Growth factors being evaluated for their role in enhancing platelet counts include interleukin 11, stem cell factor, and megakaryocyte growth and development factor (thrombopoietin) </plain></SENT>
<SENT sid="10" pm="."><plain>Newer strategies to improve the outcome of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> should be based on an increased understanding of the biology of these disorders </plain></SENT>
</text></document>